Apax Partners has appointed Prof. Dr Kai Deusch, 43, as a director within its biotech team. Professor Deusch has 15 years experience in clinical practice and research. In 1996 he joined the management consultancy, McKinsey, and in 1999 he founded the Medicis Group, a specialist healthcare and life sciences venture capital company. While at McKinsey he founded the McKinsey New Venture Practice, which provides strategic and operative advice to new enterprises in the life science sector.
Prof. Dr Kai Deusch has directed a department of clinical and experimental immunology at the University of Tubingen. His clinical and scientific training included work at the University of Minnesota in Minneapolis, Harvard University in Cambridge/Massachusetts, the Hammersmith Hospital of the University of London, Johannes-Gutenberg University in Mainz, as well as the Technical University of Munich, where he qualified as a professor in internal medicine in 1994 and since then he has held a lectureship.
Dr Paul Haycock, director of Apax Partners, said: “Kai’s clinical practice, research and venture capital experience fit our team profile perfectly – he will make a significant contribution to our future life science investments.”
Professor Deusch will join the company in its Munich Office on June 1, 2001.